ArticleRisk management and healthcare policy2023

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.

Chongchong Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.